These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Rates of cognitive change in Alzheimer disease: observations across a decade of placebo-controlled clinical trials with donepezil. Jones RW; Schwam E; Wilkinson D; Waldemar G; Feldman HH; Zhang R; Albert K; Schindler R Alzheimer Dis Assoc Disord; 2009; 23(4):357-64. PubMed ID: 19561444 [TBL] [Abstract][Full Text] [Related]
43. Speech-related parameters are sensitive measures of acetylcholinesterase inhibitor therapy in mild Alzheimer's disease. Hegedűs É; Pákáski M; Gosztolya G; Hoffmann I; Kovács I; Kálmán J PLoS One; 2024; 19(8):e0308409. PubMed ID: 39163290 [TBL] [Abstract][Full Text] [Related]
44. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Doody RS; Dunn JK; Clark CM; Farlow M; Foster NL; Liao T; Gonzales N; Lai E; Massman P Dement Geriatr Cogn Disord; 2001; 12(4):295-300. PubMed ID: 11351141 [TBL] [Abstract][Full Text] [Related]
45. Personalized Prediction of Alzheimer's Disease and Its Treatment Effects by Donepezil: An Individual Participant Data Meta-Analysis of Eight Randomized Controlled Trials. Yoshida K; Seo M; Luo Y; Sahker E; Cipriani A; Leucht S; Iwatsubo T; Efthimiou O; Furukawa TA J Alzheimers Dis; 2022; 89(4):1143-1157. PubMed ID: 35988219 [TBL] [Abstract][Full Text] [Related]
46. Goal setting and attainment in Alzheimer's disease patients treated with donepezil. Rockwood K; Graham JE; Fay S; J Neurol Neurosurg Psychiatry; 2002 Nov; 73(5):500-7. PubMed ID: 12397141 [TBL] [Abstract][Full Text] [Related]
48. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. Jones RW; Soininen H; Hager K; Aarsland D; Passmore P; Murthy A; Zhang R; Bahra R Int J Geriatr Psychiatry; 2004 Jan; 19(1):58-67. PubMed ID: 14716700 [TBL] [Abstract][Full Text] [Related]
49. Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. Dubois B; Tolosa E; Katzenschlager R; Emre M; Lees AJ; Schumann G; Pourcher E; Gray J; Thomas G; Swartz J; Hsu T; Moline ML Mov Disord; 2012 Sep; 27(10):1230-8. PubMed ID: 22915447 [TBL] [Abstract][Full Text] [Related]
50. Early- and subsequent- response of cognitive functioning in Alzheimer's disease: Individual-participant data from five pivotal randomized clinical trials of donepezil. Levine SZ; Goldberg Y; Yoshida K; Samara M; Cipriani A; Iwatsubo T; Leucht S; Furukawa TA J Psychiatr Res; 2022 Apr; 148():159-164. PubMed ID: 35124395 [TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial. Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM; Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715 [TBL] [Abstract][Full Text] [Related]
53. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results. Amenta F; Carotenuto A; Fasanaro AM; Rea R; Traini E J Neurol Sci; 2012 Nov; 322(1-2):96-101. PubMed ID: 22959283 [TBL] [Abstract][Full Text] [Related]
54. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. Dichgans M; Markus HS; Salloway S; Verkkoniemi A; Moline M; Wang Q; Posner H; Chabriat HS Lancet Neurol; 2008 Apr; 7(4):310-8. PubMed ID: 18296124 [TBL] [Abstract][Full Text] [Related]
55. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review. Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N Int J Technol Assess Health Care; 2002; 18(3):497-507. PubMed ID: 12391943 [TBL] [Abstract][Full Text] [Related]
56. Donepezil treatment and Alzheimer disease: can the results of randomized clinical trials be applied to Alzheimer disease patients in clinical practice? Tinklenberg JR; Kraemer HC; Yaffe K; Ross L; Sheikh J; Ashford JW; Yesavage JA; Taylor JL Am J Geriatr Psychiatry; 2007 Nov; 15(11):953-60. PubMed ID: 17974866 [TBL] [Abstract][Full Text] [Related]
57. Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study. Florian H; Meier A; Gauthier S; Lipschitz S; Lin Y; Tang Q; Othman AA; Robieson WZ; Gault LM J Alzheimers Dis; 2016; 51(4):1237-47. PubMed ID: 26967214 [TBL] [Abstract][Full Text] [Related]
58. Cognitive Improvement during Treatment for Mild Alzheimer's Disease with a Chinese Herbal Formula: A Randomized Controlled Trial. Zhang Y; Lin C; Zhang L; Cui Y; Gu Y; Guo J; Wu D; Li Q; Song W PLoS One; 2015; 10(6):e0130353. PubMed ID: 26076022 [TBL] [Abstract][Full Text] [Related]
59. Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy. Modrego PJ; Fayed N; Errea JM; Rios C; Pina MA; Sarasa M Eur J Neurol; 2010 Mar; 17(3):405-12. PubMed ID: 19874395 [TBL] [Abstract][Full Text] [Related]
60. Prediction of psychiatric response to donepezil in patients with mild to moderate Alzheimer's disease. Tanaka M; Namiki C; Thuy DH; Yoshida H; Kawasaki K; Hashikawa K; Fukuyama H; Kita T J Neurol Sci; 2004 Oct; 225(1-2):135-41. PubMed ID: 15465097 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]